- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Ionis Pharmaceuticals Inc(IONS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IONS
11/13/2026: IONS (2-star) is currently NOT-A-BUY. Pass it for now.
Ionis Pharmaceuticals is a commercial-stage biotechnology company specializing in RNA-targeted therapeutics for serious and rare diseases. The company's main strengths lie in its foundational antisense technology platform, validated royalty streams from partnered drugs like Spinraza, and a robust balance sheet. Its primary growth opportunity stems from the commercial expansion of newly launched treatments such as Wainua and Tryngolza. However, key risks include persistent operating cash burn, execution hurdles with recent product rollouts, and intense competition from alternative genetic medicine modalities. The stock suits growth-oriented biotech investors willing to tolerate clinical volatility while monitoring long-term pipeline execution and cash-flow milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Appeals to growth investors seeking exposure to innovative RNA platform pipelines, though near-term revenue growth remains lumpy. |
| Momentum investor | Strong fit while signal remains positive | Momentum appeal depends closely on positive clinical trial readouts and regulatory catalysts driving short-term price movement. |
| Value investor | Weak fit | Lacks consistent profitability and traditional earnings metrics, making traditional value valuation challenging. |
| Dividend investor | Weak fit | The company does not pay dividends, reinvesting all capital into drug development. |
| Low-risk investor | Weak fit | High clinical trial risks and stock price volatility make it unsuitable for conservative, low-risk mandates. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results and regulatory decisions frequently trigger sharp share price swings. |
| Valuation risk | Medium / high | Valuation relies heavily on long-term pipeline potential rather than current earnings multiples. |
| Competition risk (RNA and genetic medicine rivals) | High | Aggressive competition from alternative modalities like siRNA and gene editing threatens market share. |
| Business quality | Medium | Strong proprietary platform and high-profile pharma partnerships validate structural quality, offset by lack of net profitability. |
| Dividend income | Low / none | No dividend is paid to investors. |
| Execution risk | High | Successful commercial rollouts and clinical trial execution are vital to achieving positive cash flow. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.84B USD | Price to earnings Ratio - | 1Y Target Price 68.48 |
Price to earnings Ratio - | 1Y Target Price 68.48 | ||
Volume (30-day avg) 4.0M shares | Beta 0.4 | 52 Weeks Range 27.25 - 86.74 | Updated Date 11/15/2026 |
52 Weeks Range 27.25 - 86.74 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.35 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 85.43% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Product Sales | Direct sales of proprietary rare disease and specialty medicines. | Direct product sales represent high-quality revenue, though they currently form a smaller portion of total sales. |
| Royalties and Licensing | Royalty percentages on partner-commercialized drugs like Spinraza and milestone payments. | Royalties provide a steady, lower-overhead income stream backed by major pharmaceutical distributors. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 90.91 | Enterprise Value 4.59B | Price to Sales(TTM) 5.04 |
Enterprise Value 4.59B | Price to Sales(TTM) 5.04 | ||
Enterprise Value to Revenue 4.78 | Enterprise Value to EBITDA 135.77 | Shares Outstanding 166.55M | Shares Floating 165.18M |
Shares Outstanding 166.55M | Shares Floating 165.18M | ||
Percent Insiders 1.48 | Percent Institutions 111.68 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

